Literature DB >> 14738708

Update on pharmacotherapy of borderline personality disorder.

Mary C Zanarini1.   

Abstract

Pharmacotherapy is a very common form of treatment for borderline personality disorder or its concomitant disorders. This paper reviews all the open-label and placebo-controlled trials of second generation medications studied in samples of well-defined borderline patients. Most of the medications studied in double-blind, placebo-controlled trials were efficacious. Most of these medications were also useful in treating symptoms of affective dysregulation and impulsive aggression, which have been suggested to be the core dimensions of psychopathology of underlying borderline personality disorder. Taken together, the results of these studies suggest that the choice of medication can be guided as much by tolerability and safety as by symptom presentation. It also suggests that the common practice of polypharmacy, which has no empiric support, may be unnecessary for most patients with borderline personality disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738708     DOI: 10.1007/s11920-004-0041-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  30 in total

1.  Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

Authors:  S C Schulz; K L Camlin; S A Berry; J A Jesberger
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

2.  Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.

Authors:  O C Pinto; H S Akiskal
Journal:  J Affect Disord       Date:  1998-12       Impact factor: 4.839

3.  SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.

Authors:  Thomas Rinne; Wim van den Brink; Luuk Wouters; Richard van Dyck
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

4.  Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology.

Authors:  Mary C Zanarini; Anna A Vujanovic; Elizabeth A Parachini; Jennifer L Boulanger; Frances R Frankenburg; John Hennen
Journal:  J Pers Disord       Date:  2003-06

5.  An open trial of valproate in borderline personality disorder.

Authors:  D J Stein; D Simeon; M Frenkel; M N Islam; E Hollander
Journal:  J Clin Psychiatry       Date:  1995-11       Impact factor: 4.384

6.  Venlafaxine in the treatment of borderline personality disorder.

Authors:  P J Markovitz; S C Wagner
Journal:  Psychopharmacol Bull       Date:  1995

7.  Axis I comorbidity of borderline personality disorder.

Authors:  M C Zanarini; F R Frankenburg; E D Dubo; A E Sickel; A Trikha; A Levin; V Reynolds
Journal:  Am J Psychiatry       Date:  1998-12       Impact factor: 18.112

8.  Divalproex sodium as a treatment for borderline personality disorder.

Authors:  J A Wilcox
Journal:  Ann Clin Psychiatry       Date:  1995-03       Impact factor: 1.567

9.  Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  J Clin Psychiatry       Date:  2004-01       Impact factor: 4.384

10.  Fluoxetine trial in borderline personality disorder.

Authors:  J R Cornelius; P H Soloff; J M Perel; R F Ulrich
Journal:  Psychopharmacol Bull       Date:  1990
View more
  8 in total

1.  Self-mutilation and pharmacotherapy.

Authors:  Brian Daniel Smith
Journal:  Psychiatry (Edgmont)       Date:  2005-10

2.  Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up.

Authors:  Nancee Blum; Don St John; Bruce Pfohl; Scott Stuart; Brett McCormick; Jeff Allen; Stephan Arndt; Donald W Black
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

3.  The 10-year course of physically self-destructive acts reported by borderline patients and axis II comparison subjects.

Authors:  M C Zanarini; F R Frankenburg; D B Reich; G Fitzmaurice; I Weinberg; J G Gunderson
Journal:  Acta Psychiatr Scand       Date:  2008-02-01       Impact factor: 6.392

4.  A longitudinal perspective on personality disorder symptomatology.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2008-01

Review 5.  Borderline personality disorder: considerations for inclusion in the Massachusetts parity list of "biologically-based" disorders.

Authors:  Mary Ellen Foti; Jeffrey Geller; Laura S Guy; John G Gunderson; Brian A Palmer; Lisa M Smith
Journal:  Psychiatr Q       Date:  2011-06

6.  Borderline personality disorder: current drug treatments and future prospects.

Authors:  Bayanne Olabi; Jeremy Hall
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

7.  Predictors of response to Systems Training for Emotional Predictability and Problem Solving (STEPPS) for borderline personality disorder: an exploratory study.

Authors:  D W Black; J Allen; D St John; B Pfohl; B McCormick; N Blum
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

Review 8.  Psychotherapy of borderline personality disorder.

Authors:  M C Zanarini
Journal:  Acta Psychiatr Scand       Date:  2009-11       Impact factor: 6.392

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.